Andarix

Rhenium Re 188 P2045
Andarix Pharmaceuticals, Inc.
New Radiopharmaceutical For the Treatment of Lung and Other Cancers Print E-mail
Rhenium Re 188 P2045 is a radiopharmaceutical that combines a high-affinity somatostatin receptor-binding peptide with the high-energy, beta-emitting radionuclide Rhenium-188. It has been shown to inhibit the growth of lung and other tumor xenografts in animal models. In a Phase 1 dose escalation study, in which the drug was well tolerated, four of eight patients presenting with progressive non-small cell lung cancer achieved stable disease at eight weeks. Median overall survival was 11.5 months.
Read more...